ImmunoGen - Antibody-Drug Conjugate's Unit Acquisition

ImmunoGen - Antibody-Drug Conjugate raised a round of funding on May 24, 2017. Investors include Debiopharm Group.

ImmunoGen (IMGN) is a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. Antibody-Drug Conjugate is an anti-CD37 non-Hodgkin lymphoma…

Articles about ImmunoGen - Antibody-Drug Conjugate's Unit Acquisition: